Close this search box.

LiteVax started Phase 1 trial with a novel, adjuvanted, low-dose influenza vaccine (TETRALITE)

Oss/Ghent, Netherlands/Belgium, October 2022 – INDIGO, a consortium of public and
private R&D organisations for development of improved influenza virus vaccines, has started
a Phase 1 trial with a novel, adjuvanted, low-dose seasonal influenza vaccine. Safety,
tolerability, and immunogenicity of TETRALITE, a combination of 1/5th of a dose of a licensed
influenza vaccine and the novel LiteVax Adjuvant, will be investigated in healthy subjects.

In nonclinical studies, TETRALITE generated unprecedently high immune responses without
detectable systemic or local side-effects. This first-in-human trial marks an important
milestone in the collaborative research of the Center for Vaccinology (Ghent), HarmonyCR
(Melle) and LiteVax BV (Oss) towards a better and affordable seasonal influenza vaccine for
the world.

LiteVax BV is a biopharmaceutical company focusing on the development of novel vaccine
adjuvants. The versatile adjuvant technology exploited in TETRALITE is based on a synthetic
carbohydrate fatty acid monosulphate ester ( and investigated with other

The Centre for Vaccinology (CEVAC), Ghent University Hospital and Ghent University, is
dedicated to contributing to the development of effective vaccines for the prevention of
infectious diseases. CEVAC has a clinical trial unit and an immunomonitoring lab with over 25
years of experience in conducting clinical vaccine trials using the highest quality standards

INDIGO is an interdisciplinary consortium consisting of 16 partners from India, EU and US
funded by the European Union Horizon 2020 program and the Department of Biotechnology,
Ministry of Science and Technology, Government of India (grant ID 874653;
For more information on the INDIGO Project, please contact
For more information on the Clinical Trial, please contact
For more information on the LiteVax Adjuvant, please contact

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.